The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of ...

The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into ...

Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to ...

AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...

J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment ...

Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have ...

The startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a ...

The startup is built around technology it claims can help get after known, but undruggable cancer targets and design ...

On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall ...

The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a ...

The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy.

Explore how integrated scenario modeling helps pharma leaders navigate pricing uncertainty and the complexity of global ...